Acceso usuarios
Diane S. Aschenbrenner
* A new treatment is now available for postmenopausal women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer. Palbociclib (Ibrance) inhibits cyclin-dependent kinases 4 and 6.
